Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06452212
Status:
COMPLETED
Last Update Posted:
2024-07-15
First Post:
2024-06-05
Brief Title:
Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
Sponsor:
Astellas Pharma Korea Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Non-Interventional Modified Delphi Study to Establish Consensus Recommendations on the Optimal Management of Metastatic Hormone-Sensitive Prostate Cancer mHSPC Patients in South Korea
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea and to provide clinicians with a comprehensive guide to support their clinical decision making There are no secondary objectives for this study
Detailed Description:
Data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals HCPs A meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None